CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 54 enrolled
Drug / intervention
D-cycloserine +2 moredrug
Likely dose
D-cycloserine 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00963924
NCT00963924N/ACompleted

A Placebo-controlled Trial of D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia

Massachusetts General Hospital·interventional·Posted Aug 24, 2009·Updated Feb 6, 2018

In Brief

A clinical study evaluating D-cycloserine, Placebo, and 1 other intervention for Schizophrenia. Completed, enrolled 54 participants across 1 site.

Detailed Summary

This study seeks to examine the effects of D-cycloserine augmentation on cognitive remediation for patients diagnosed with schizophrenia. We will test the hypotheses that D-cycloserine will significantly improve cognitive performance, negative symptoms, and measures of functioning compared to placebo when combined with eight weeks of cognitive remediation. We expect that these effects will persist when assessed at six-month follow up.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 24, 2009
Enrollment StartAug 1, 2009
Primary CompletionMay 1, 2011
Study CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.9 years ago

Interventions

D-cycloserinedrug

50 mg by mouth one hour before first cognitive remediation session each week for eight weeks.

Placebodrug

Placebo by mouth one hour before first cognitive remediation session each week for eight weeks.

Cognitive Remediationbehavioral

40 one-hour daily sessions of cognitive remediation (Brain Fitness Program) over eight weeks.